CRC
California Resources Corp
$54.22
+0.70
(+1.31%)
Mkt Cap
4.81B
Volume
471,843
52W Range
43.245-71.98
Sector
Energy
Beta
0.90
EPS (TTM)
-1.33 USD
P/E Ratio
10.72
Revenue (TTM)
4.01B USD
Rev Growth (5Y)
+17.5%
EPS Growth (5Y)
-28.7%
AlphaVal · Fair Value
What we estimate one share is worth
$62.94
Fair Value
weak signal
13.9% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B-
Oil & Gas E&P
65.1 / 100 composite
An oil & gas explorer and producer — graded A–F vs. similar companies.
Company Description
California Resources Corporation operates as an independent energy and carbon management company in the United States. The company operates in two segments, Oil and Natural Gas, and Carbon Management. It explores, develops, and produces crude oil, oil condensate, natural gas liquids and natural gas to california refineries, marketers, and other purchasers. The company also provides Carbon TerraVault which builds, installs, operates, and maintains CO2 capture equipment, transportation assets, and storage facilities. In addition, it owns and operates power generation facilities, as well as smaller gas-fired power plants used to generate power for oil and natural gas operations. The company was incorporated in 2014 and is based in Long Beach, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.60B | 2.96B | 2.81B | 3.26B | 2.56B | 1.61B | 2.69B | 3.06B | 2.10B | 1.75B | 2.35B | 4.18B |
| Net Income | 363.00M | 376.00M | 564.00M | 524.00M | 612.00M | 1.88B | (28.00M) | 328.00M | (266.00M) | 279.00M | (3.55B) | (1.43B) |
| EPS | 4.17 | 4.74 | 8.10 | 6.94 | 7.46 | 22.59 | -0.57 | 6.77 | -6.26 | 6.76 | -92.79 | -37.54 |
| Free Cash Flow | 543.00M | 350.00M | 460.00M | 311.00M | 466.00M | 59.00M | 221.00M | (229.00M) | (123.00M) | 55.00M | 2.00M | 351.00M |
| FCF / Share | 6.24 | 4.41 | 6.61 | 4.12 | 5.68 | 0.71 | 4.51 | -4.83 | -2.89 | 1.36 | 0.05 | 9.19 |
| Operating CF | 865.00M | 605.00M | 645.00M | 690.00M | 660.00M | 106.00M | 676.00M | 461.00M | 248.00M | 130.00M | 403.00M | 2.37B |
| Total Assets | 7.40B | 7.13B | 4.00B | 3.97B | 3.85B | 3.07B | 6.96B | 7.16B | 6.21B | 6.35B | 7.05B | 12.50B |
| Total Debt | 1.36B | 1.22B | 610.00M | 662.00M | 637.00M | 639.00M | 5.04B | 5.25B | 5.31B | 5.27B | 6.14B | 6.36B |
| Cash & Equiv | 132.00M | 372.00M | 496.00M | 307.00M | 305.00M | 28.00M | 17.00M | 17.00M | 20.00M | 12.00M | 12.00M | 14.00M |
| Book Value | 3.67B | 3.54B | 2.22B | 1.86B | 1.69B | 1.14B | (389.00M) | (361.00M) | (814.00M) | (557.00M) | (916.00M) | 2.61B |
| Return on Equity | 0.10 | 0.11 | 0.25 | 0.28 | 0.36 | 1.65 | N/A | N/A | N/A | N/A | N/A | -0.55 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30B | 967.00M | 871.00M | 878.00M | 821.00M | 906.00M | 926.00M | 997.00M | 509.00M | 525.00M | 607.00M | 664.00M |
| Net Income | 514.00M | (711.00M) | 12.00M | 64.00M | 172.00M | 115.00M | 33.00M | 345.00M | 8.00M | (10.00M) | 188.00M | (22.00M) |
| EPS | 5.79 | -8.02 | 0.14 | 0.76 | 1.93 | 1.27 | 0.36 | 3.86 | 0.12 | -0.14 | 2.74 | -0.32 |
| Free Cash Flow | 114.00M | (22.00M) | 116.00M | 187.00M | 109.00M | 131.00M | 118.00M | 141.00M | 66.00M | 25.00M | 57.00M | 71.00M |
| FCF / Share | 1.28 | -0.25 | 1.33 | 2.22 | 1.22 | 1.45 | 1.30 | 1.58 | 0.97 | 0.36 | 0.82 | 1.03 |
| Operating CF | 263.00M | 109.00M | 236.00M | 278.00M | 165.00M | 186.00M | 206.00M | 220.00M | 100.00M | 79.00M | 123.00M | 104.00M |
| Total Assets | 7.10B | 7.15B | 7.40B | 6.75B | 6.71B | 6.83B | 7.13B | 7.13B | 4.49B | 3.91B | 4.00B | 3.95B |
| Total Debt | 1.35B | 1.38B | 1.36B | 1.10B | 1.09B | 1.10B | 1.22B | 1.22B | 1.24B | 616.00M | 610.00M | 655.00M |
| Cash & Equiv | 56.00M | 40.00M | 132.00M | 196.00M | 72.00M | 214.00M | 372.00M | 241.00M | 1.03B | 403.00M | 496.00M | 479.00M |
| Book Value | 3.40B | 2.92B | 3.67B | 3.44B | 3.41B | 3.52B | 3.54B | 3.50B | 2.05B | 2.09B | 2.22B | 2.05B |
| Return on Equity | 0.15 | -0.24 | 0.00 | 0.02 | 0.05 | 0.03 | 0.01 | 0.10 | 0.00 | -0.00 | 0.08 | -0.01 |
CRC News
Should Value Investors Buy California Resources (CRC) Stock?
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
California Resources Corporation Schedules Third Quarter 2026 Earnings Conference Call
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
Head to Head Comparison: California Resources (NYSE:CRC) versus Kinetik (NYSE:KNTK)
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
California Resources to Divest Uinta Basin Assets for $90 Million
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)